231 related articles for article (PubMed ID: 7523000)
1. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.
Badonnel Y; Barbé F; Legagneur H; Poncelet E; Schweitzer M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):155-62. PubMed ID: 7523000
[TBL] [Abstract][Full Text] [Related]
2. Inhibin: a new circulating marker of hydatidiform mole?
Yohkaichiya T; Fukaya T; Hoshiai H; Yajima A; de Kretser DM
BMJ; 1989 Jun; 298(6689):1684-6. PubMed ID: 2503176
[TBL] [Abstract][Full Text] [Related]
3. Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
Pautier P; Ghione S; Brailly-Tabard S; Lhommé C; Morice P; Bidart JM
Hum Reprod; 2001 Nov; 16(11):2434-7. PubMed ID: 11679534
[TBL] [Abstract][Full Text] [Related]
4. Circulating inhibin forms in patients with hydatidiform mole.
Kato T; Seki K; Matsui H; Sekiya S
Gynecol Obstet Invest; 2002; 54(2):114-7. PubMed ID: 12566755
[TBL] [Abstract][Full Text] [Related]
5. Hydatidiform mole and post-evacuation regression patterns of serum beta human chorionic gonadotrophin.
Kamariah K; Satgunasingam N; Nasri NM; Ng KY
Med J Malaysia; 1993 Mar; 48(1):40-5. PubMed ID: 7688063
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of serum inhibin, 17 beta-estradiol and progesterone in cases of hydatidiform mole.
Hegab HM; Schindler AE
Gynecol Endocrinol; 2004 Feb; 18(2):107-13. PubMed ID: 15195503
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoassay of the serum free beta-subunit of human chorionic gonadotropin in trophoblastic disease.
Fan C; Goto S; Furuhashi Y; Tomoda Y
J Clin Endocrinol Metab; 1987 Feb; 64(2):313-8. PubMed ID: 2432080
[TBL] [Abstract][Full Text] [Related]
8. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
Zhang WY; Yen GL
Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
10. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
11. Polypeptide nicks cause erroneous results in assays of human chorionic gonadotropin free beta-subunit.
Kardana A; Cole LA
Clin Chem; 1992 Jan; 38(1):26-33. PubMed ID: 1370771
[TBL] [Abstract][Full Text] [Related]
12. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve.
Morrow P; Nakamura R; Schlaerth J; Gaddis O; Eddy G
Am J Obstet Gynecol; 1985 Apr; 151(7):906-14. PubMed ID: 2580438
[TBL] [Abstract][Full Text] [Related]
13. Serum SP1 and hCG beta-subunit (hCG beta) levels in choriocarcinoma, invasive mole, and hydatidiform mole--clinical significance of SP1/hCG beta ratio.
Sakuragi N
Gynecol Oncol; 1982 Jun; 13(3):393-8. PubMed ID: 6178652
[No Abstract] [Full Text] [Related]
14. The level of beta-subunit of human chorionic gonadotrophin in benign hydatidiform mole.
Tangtakul S; Srisupundit S
J Med Assoc Thai; 1988 Mar; 71 Suppl 1():111-3. PubMed ID: 2458424
[No Abstract] [Full Text] [Related]
15. Serum activin A and inhibin A. New clinical markers for hydatidiform mole.
Florio P; Severi FM; Cobellis L; Danero S; Bomè A; Luisi S; Petraglia F
Cancer; 2002 May; 94(10):2618-22. PubMed ID: 12173329
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease.
Duc HN; van Trommel NE; Sweep FC; Massuger LF; Thomas CM
Int J Biol Markers; 2006; 21(1):45-9. PubMed ID: 16711513
[TBL] [Abstract][Full Text] [Related]
17. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy.
Florio P; Luisi S; Casarosa E; Genazzani AR; Pautier P; Lhommé C; Bidart JM; Driul PG; Petraglia F
J Endocrinol Invest; 1998 Mar; 21(3):166-9. PubMed ID: 9591212
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunoassay of free beta-subunit of human chorionic gonadotropin in diagnosis of high-risk and low-risk gestational trophoblastic disease.
Khazaeli MB; Buchina ES; Pattillo RA; Soong SJ; Hatch KD
Am J Obstet Gynecol; 1989 Feb; 160(2):444-9. PubMed ID: 2464935
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles.
Berkowitz R; Ozturk M; Goldstein D; Bernstein M; Hill L; Wands JR
Obstet Gynecol; 1989 Aug; 74(2):212-6. PubMed ID: 2473429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
